Navigation Links
JDRF announces diabetes research program with Johnson & Johnson
Date:12/17/2009

NEW YORK, Dec. 17, 2009 The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin working with The Johnson & Johnson Corporate Office of Science and Technology, and its affiliates, to speed the development of drug targets and pathways to promote the survival and function of insulin-producing cells in people who have diabetes. The program will look to fund research at academic centers around the world that could eventually lead to novel drug targets and industry collaborations for the treatment of type 1 diabetes.

The joint program will solicit grant proposals from academia and medical research foundations for one- or two-year research projects. The research will focus on agents and compounds that safely promote survival and function of beta cells the cells within the pancreas that produce insulin, and that are lost in the immune attack that causes type 1 diabetes. Preserving or maintaining beta cell mass and activity in people with type 1 diabetes can reduce insulin requirements, make controlling the disease easier and more effective, and lower the risk of both short and long-term complications of the disease..

"This program will clearly help accelerate the translation of basic research into therapies useful in the treatment of diabetes," said Alan J. Lewis, Ph.D., President and Chief Executive Officer of JDRF. "By creating this novel incubator program to support early stage research with a company known for first-class research and significant experience in the commercialization of products, we believe we can increase the number of viable drug targets identified and fundamentally change the pace of diabetes research."

Funding decisions will be led by a combined review committee consisting of representatives from the JDRF and The Johnson & Johnson Corporate Office of Science and Technology and its affiliates, with oversight from a Scientific Advisory Board and JDRF volunteers.

"Beta cell survival is a critical research focus to advance the understanding of the natural history of diabetes and importantly, where to intervene to slow or arrest the progression of this disease," said Martin Fitchet, M.D, Therapeutic Area Head, Cardiovascular and Metabolism for Johnson & Johnson Pharmaceutical Research and Development, L.L.C. "Establishing this alliance with The Juvenile Diabetes Research Foundation is a part of our commitment to access external innovation to drive discovery and development of new therapies for the patients who most need them."

The program aims to contribute to medical research funding in the discovery of better treatments for diabetes, facilitating cooperation between the pharmaceutical industry and universities in with the potential to lead to drug targets and products.


'/>"/>

Contact: Jillian Lubarsky
jlubarsky@jdrf.org
212-479-7626
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
2. LaserCard Corporation Announces Expansion of Middle East Project
3. BIO-key(R) Announces Contracts for New Criminal Justice Data Sharing Solution
4. Balzan Foundation announces 2007 winners
5. The American Society of Plant Biologists announces 2007 awards
6. ASPB announces Summer Undergraduate Research Fellowship 2007 recipients
7. NIST announces 56 new awards for innovative technology research and development
8. Titanium Group Announces Contract With Haitong Securities
9. Measurement Specialties, Inc. Announces Impact of German Business Tax Reform 2008 Resulting in Lower Combined German Tax Rate - Impacts 2Q08 Reported Financial Results
10. FIJI Water announces sustainable growth initiative with commitment to help mitigate climate change
11. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/22/2016)... June 22, 2016  The American College of Medical Genetics ... Executive Magazine as one of the fastest-growing trade shows ... at the Bellagio in Las Vegas . ... percentage of growth in each of the following categories: net ... and number of attendees. The 2015 ACMG Annual Meeting was ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita ... miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the subject of ... now. , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
Breaking Biology Technology: